- Dacetuzumab
-
Dacetuzumab ? Monoclonal antibody Type Whole antibody Source Humanized (from mouse) Target CD40 Clinical data Pregnancy cat. ? Legal status ? Identifiers CAS number 880486-59-9 ATC code None UNII UT59FF4T5X Chemical data Formula C6452H9964N1732O1998S42 Mol. mass 145.1 kDa (for the peptide) (what is this?) (verify) Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma[2] and hematological malignancies.[3]
This drug was developed by Seattle Genetics, Inc.
References
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab, American Medical Association.
- ^ Advani, R.; Forero-torres, A.; Furman, R. R.; Rosenblatt, J. D.; Younes, A.; Ren, H.; Harrop, K.; Whiting, N. et al. (2009). "Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma". Journal of Clinical Oncology 27 (26): 4371–4377. doi:10.1200/JCO.2008.21.3017. PMID 19636010.
- ^ Khubchandani; Czuczman, M. S.; Hernandez-Ilizaliturri, F. J. (2009). "Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies". Current opinion in investigational drugs (London, England : 2000) 10 (6): 579–587. PMID 19513947.
Monoclonal antibodies for tumors Tumor ("-t(u[m])-") Human ("-tumu-")Adecatumumab • Belimumab • Cixutumumab • Conatumumab • Daratumumab • Drozitumab • Figitumumab • Ganitumab • Glembatumumab vedotin • Intetumumab • Iratumumab • Lexatumumab • Lucatumumab • Mapatumumab • Narnatumab • Necitumumab • Ofatumumab • Olaratumab • Panitumumab • Pritumumab • Radretumab • Rilotumumab • Robatumumab • Teprotumumab • Votumumab • Zalutumumab
"-melu-" (melanoma): FlanvotumabMouse ("-tumo-")Altumomab pentetate • Anatumomab mafenatox • Arcitumomab • Bectumomab • Blinatumomab • CC49 • Detumomab • Ibritumomab tiuxetan • Minretumomab • Mitumomab • Moxetumomab pasudotox • Naptumomab estafenatox • Nofetumomab merpentan • Pemtumomab† • Pintumomab • Racotumomab • Satumomab pendetide • Taplitumomab paptox • Tenatumomab • Tositumomab • 3F8
"-govo-" (ovarian tumor): Abagovomab • Igovomab • Oregovomab
"-pro-" (prostate tumor): Capromab pendetide
"-colo-" (colonic tumor): Edrecolomab • Nacolomab tafenatoxChimeric ("-tuxi-")Amatuximab • Bavituximab • Brentuximab vedotin • Cetuximab • Ensituximab • Girentuximab • Indatuximab ravtansine • Rituximab • Siltuximab • Ublituximab
"-mexi-" (melanoma): EcromeximabHumanized ("-tuzu-")Afutuzumab • Alemtuzumab • Bevacizumab • Bivatuzumab mertansine • Cantuzumab mertansine • Cantuzumab ravtansine • Citatuzumab bogatox • Clivatuzumab tetraxetan • Dacetuzumab • Dalotuzumab • Elotuzumab† • Etaracizumab • Farletuzumab • Ficlatuzumab • Gemtuzumab ozogamicin • Inotuzumab ozogamicin • Labetuzumab • Lintuzumab • Lorvotuzumab mertansine • Matuzumab§ • Milatuzumab • Nimotuzumab • Onartuzumab • Oportuzumab monatox • Pertuzumab • Sibrotuzumab • Tacatuzumab tetraxetan • Tigatuzumab • Trastuzumab • Tucotuzumab celmoleukin • VeltuzumabRat/mouse hybrid ("-tumaxo-")This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.